logo
Share SHARE
FONT-SIZE Plus   Neg

Silence Therapeutics Promotes Tony Sedgwick To CEO - Quick Facts

Silence Therapeutics plc (SLN.L) announced the promotion of Tony Sedgwick to the role of chief executive from chief business officer, effective immediately, and the departure of Thomas Christély who has resigned as a director of the company for personal reasons but would ensure a smooth transition.

Anthony David Sedgwick, with an extensive experience from European life science companies including over 15 years at Roche, joined Silence in September 2011 to lead a new business development team. Prior to joining
Silence, Tony was CEO of Novacta and Chairman of the Norwegian biotech company Plastid AS. Earlier, Tony was also CEO of two acquired companies namely Daniolabs Ltd. and Cambridge Biotechnology Ltd.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Treasury Secretary Steven Mnuchin's comments about the Lego Batman movie that he produced has raised questions from ethical groups whether he violated federal ethics rules that prohibit the promotion of products. Mnuchin, a former Hollywood producer, was asked several questions related to movies at an Axios event in Washington on Friday. A United Airlines gate agent barred two teenage girls from boarding a flight on Sunday for wearing leggings, noting that they failed to meet a dress code for special pass travelers. United spokesman Jonathan Guerin responded that the two girls traveling with a companion would not have been turned away for wearing leggings if they were paying customers. Alteryx, Inc., a provider of self-service data analytics software, is the latest tech company to go public in March. Alteryx said it has priced its IPO of 9 million shares of its Class A common stock at $14 per share, at the top end of its range of $12 to $14 per share.
comments powered by Disqus
Follow RTT